Aiming at an ‘Undruggable” target, Pyrotech’s class 1 small-molecule candidate gets approved for sepsis clinical trials
On August 4, Pyrotech Therapeutics (“Pyrotech”) announced that its independently developed small-molecule pyroptosis inhibitor, PTT-121, has been approved for clinical trials in China, intended for the treatment of sepsis and septic shock.…
Kelun Biotech seeks marketing approval on sac-TMT for the first-line treatment of PD-L1-negative TNBC
On July 30, 2026, Sichuan Kelun Biotech Co., Ltd. (“Kelun”) announced that its independently developed antibody-drug conjugate (ADC) targeting human trophoblast surface antigen 2 (TROP2), sac-TMT (also known as SKB264/MK-2870) (Gitalay®), has…
XellSmart’s universal cell therapy drug for Parkinson’s disease receives Fast Track designation from the US FDA
On July 28, 2026, XellSmart Bio‘s independently developed allogeneic universal “off-the-shelf” XS411 cell therapy injection, for the treatment of Parkinson’s disease, the world’s second most prevalent neurodegenerative…
Haisco’s class 1 small-molecule PNH drug has been approved for marketing in China
Today (July 23), the National Medical Products Administration (NMPA) of China announced that it has approved the marketing of Haisco Pharmaceutical‘s Class 1 innovative drug, Succinate Spocoman tablets (HSK39297), through the priority review and…